Press Release« Back to Press Releases
BioImagene CEO, Dr Ajit Singh speaks on enabling personalized medicine through digital pathology
Cupertino, Thursday, December 4, 2008
Dr Ajit Singh, CEO of BioImagene, spoke yesterday on the importance of digital pathology in personalized medicine - a rapidly emerging field that promises to tailor diagnoses and therapies for individual patients based on their specific profiles. Dr Singh was speaking on the occasion of the California Society of Pathologists (CSP) Annual Meeting in Los Angeles, CA.
Digital pathology, a key enabler for personalized medicine, will aid clinicians in managing and interpreting data from a whole new set of diagnostic tests to select patients for specific therapies. Personalized medicine is expected to get a major push from the incoming administration of President-elect Barack Obama.
Dr. Singh said, “I came here today to talk to pathologists about necessary innovations in pathology that will impact the delivery of healthcare in the future.” He further added, “In the next decade, anatomic pathology is poised to undergo a fundamental shift from glass slides to digital images, from eyeball estimates to quantitative data, and from single marker assessment to multibiomarker analysis. This transformation will give a major push to personalized medicine. Digital pathology is one of the last missing links in this process.”
Dr Mahul Amin, Chairman, Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center also spoke at the meeting about the critical role of pathologists in the era of personalized medicine. “The traditional approach to treatment is generally reactive prescription and monitoring of the disease based on symptomatic diagnosis. Personalized healthcare incorporates molecular and genetic data of the patient and the disease to offer targeted therapy, genetic stratification and proactive intervention for early diagnosis or prevention of the disease. In contrast to the traditional approach of one size fits all treatment, personalized medicine offers the right treatment for the right person at the right time with the right dose for the right outcome and improved quality of life.
The talks by Dr. Singh and Dr. Amin stimulated considerable dialog among the Pathologists attending the conference. A tighter collaboration betweeen industry and clinicians was the underlying theme of these discussions.
Mohan Uttarwar, CSO, Bioimagene said,” Personalized medicine is leading to the development of therapeutics and diagnostics in a collaborative manner. We believe that this personalized approach to drug and diagnostic development will become a healthcare reform priority.”
Personalized medicine involves identifying genetic, genomic, and clinical information that allows accurate predictions to be made about a person’s susceptibility of developing disease, the course of disease, and its response to treatment.
About BioImagene
BioImagene is a leading provider of total digital pathology solutions for applications including clinical diagnostics and drug discovery. BioImagene products are FDA -cleared for specific clinical applications, and are intended for research use for other applications.
Media contact: Suchitra Parthasarathy
408 207 4285
www.bioimagene.com